Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.
- DOI
- 10.1186/s13023-026-04303-8
- Published
- 2026 Mar 20
- Container
- Orphanet journal of rare diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13023-026-04303-8,
title = {Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.},
author = {Holida M and Linhart A and Longo N and Wallace E and Tøndel C and Hughes D and Warnock DG and Pisani A and Eyskens F and Deegan P and Feldt-Rasmussen U and Goker-Alpan O and Mehta A and Piotti G and Fichera V and Wang M and Chertkoff R and Waldek S and Wilcox WR and Bernat JA},
year = {2026},
journal = {Orphanet journal of rare diseases},
doi = {10.1186/s13023-026-04303-8},
url = {https://doi.org/10.1186/s13023-026-04303-8}
}RIS
TY - JOUR TI - Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. AU - Holida M AU - Linhart A AU - Longo N AU - Wallace E AU - Tøndel C AU - Hughes D AU - Warnock DG AU - Pisani A AU - Eyskens F AU - Deegan P AU - Feldt-Rasmussen U AU - Goker-Alpan O AU - Mehta A AU - Piotti G AU - Fichera V AU - Wang M AU - Chertkoff R AU - Waldek S AU - Wilcox WR AU - Bernat JA PY - 2026 JO - Orphanet journal of rare diseases DO - 10.1186/s13023-026-04303-8 UR - https://doi.org/10.1186/s13023-026-04303-8 ER -
APA
M, H., A, L., N, L., E, W., C, T., D, H., DG, W., A, P., F, E., P, D., U, F., O, G., A, M., G, P., V, F., M, W., R, C., S, W., WR, W., & JA, B. (2026). Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.. Orphanet journal of rare diseases. https://doi.org/10.1186/s13023-026-04303-8
Source records
- pubmed · retrieved 2026-11-10T14:43:18.656Z